Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1)

Title: Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1)

Volume: 16 Issue: 12

Author(s): S. Poon, N. R. Birkett, S. B. Fowler, B. F. Luisi, C. M. Dobson and J. Zurdo

Affiliation:

Keywords: hGLP-1, protein aggregation, biopharmaceuticals, diabetes, amyloid fibrils, Alzheimer's disease

Abstract: The potential of human glucagon-like peptide-1 (hGLP-1) as a therapeutic agent is limited by its high aggregation propensity. We show that hGLP-1 forms amyloid-like structures that are preceded by cytotoxic aggregates, suggesting that aggregation of biopharmaceuticals could present a cytotoxic risk to patients besides the reported increased risk in immunogenicity.

Cite this article as:

Poon S., Birkett R. N., Fowler B. S., Luisi F. B., Dobson M. C. and Zurdo J., Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1), Protein & Peptide Letters 2009; 16 (12) . https://dx.doi.org/10.2174/092986609789839232